24 March 2010

# ATL1102 License Agreement with Teva Pharmaceutical Industries Ltd.

Antisense Therapeutics Ltd ("ANP" or the "Company") has received notification from Teva Pharmaceutical Industries Ltd (Teva), the licensee of ANP's drug ATL1102, of Teva's decision to discontinue further clinical development of ATL1102 and to end the license agreement.

Teva advised ANP that after performing certain steps in the development process, ATL1102 was determined to no longer be in line with Teva's preferred product profile. ANP understands that business considerations or factors contributing to Teva's decision include issues with one of the long-term toxicological studies that may require repeat of the study, lengthening the development time and time to market of the drug in light of the competitive landscape.

Whilst disappointed with Teva's decision, particularly in light of the impressive efficacy observed in the Phase 2 clinical trial, ANP will now evaluate its options with respect to further development of ATL1102 with key stakeholders including Isis Pharmaceuticals, Inc. (Nasdaq:ISIS), ANP's technology collaboration partner and the original developer of ATL1102. Similarly Isis believe that the quality of the Phase 2 trial results warrant consideration of the further development of ATL1102 and discussions are currently underway between the parties on possible paths forward.

ANP intends to move forward as quickly as possible with this evaluation, however a timeline for its completion cannot be advised at this point until the Company has fully analysed and assessed its options with respect to ATL1102 and once details of the license termination are finalised.

In addition to the review of ATL1102, the Company continues development of its pipeline projects including ATL1103 for abnormal growth and sight disorders and ATL1101 for prostate cancer.

Previously ANP has reported the successful conduct of toxicology studies of ATL1103 and its intention to move this compound forward into clinical trials proposed for 2$^{nd}$ half of 2010. Isis is currently completing manufacture of clinical supplies of ATL1103 for this study. With respect to ATL1101 for prostate cancer, ANP has generated preclinical data confirming the drug's effectiveness in suppressing human prostate cancer tumour growth in animal models. The Company remains in discussions with interested parties with regard to the further development of the drug.

ANP will continue to advise its shareholders and the market on any updates to the points noted above as and when they occur.

**Antisense Therapeutics Limited** (ASX: ANP) is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialise antisense pharmaceuticals for large unmet markets. ANP has two drugs in development and two drugs in pre-clinical research. ATL1102 (injection) has completed a Phase IIa efficacy and safety trial in patients with multiple sclerosis. ATL1103 is a second-generation antisense drug designed to lower blood IGF-I levels and is entering preclinical development as a potential treatment for acromegaly and vision disorders. ATL1102 (inhaled) is at the pre-clinical research stage as a potential treatment for asthma. ATL1101 is a second-generation antisense drug at the pre-clinical research stage being investigated as a potential treatment for prostate cancer.

**Contact Information**: Website: www.antisense.com.au
Managing Director: Mark Diamond +61 3 9827 8999
Investor Relations: Simon Watkin +61 (0) 413 153272